Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer.
Smith JD, Ludwig ML, Bhangale AD, Brummel C, Swiecicki PL, Worden FP, Chinn SB, Stucken CL, Rosko AJ, Prince MEP, Malloy KM, Casper KA, Bradford CR, Chepeha DB, Shah J, Schonewolf CA, McHugh JB, Nyati MK, Eisbruch A, Mierzwa ML, Spector ME, Brenner JC.
Smith JD, et al. Among authors: rosko aj.
Head Neck. 2023 May;45(5):1281-1287. doi: 10.1002/hed.27344. Epub 2023 Mar 18.
Head Neck. 2023.
PMID: 36932871
Clinical Trial.